Medical Cannabis Improves Symptoms in 80% of Cancer Patients, Study Finds

Study Design and Patient Population

University of Kentucky researchers surveyed 237 adults receiving radiation therapy for cancer and documented symptom relief across six categories. The study focused on patients using medical cannabis during active cancer treatment, a population underrepresented in clinical cannabis research.

Patients said they used cannabis to manage pain, nausea, anxiety, depression, appetite loss, and sleep disturbance. The survey tracked self-reported outcomes rather than placebo-controlled endpoints, reflecting real-world utilization patterns in states with medical cannabis programs.

The 80% improvement rate represents patients who reported at least moderate relief in one or more symptom categories. Researchers didn't break out efficacy by cancer type, radiation protocol, or cannabis delivery method.

Symptom Relief and Quality-of-Life Outcomes

Four in five patients reported measurable relief. Pain and nausea topped the list. The data aligns with earlier observational studies from Israel and Canada showing similar efficacy rates for cannabis in oncology supportive care.

Key findings include:

• Pain relief was the most frequently reported benefit, consistent with cannabis's role as an adjunct analgesic in cancer care.
• Nausea and appetite improvement were cited by patients undergoing chemotherapy concurrent with radiation.
• Anxiety and sleep disturbance improved in a majority of respondents, though the study didn't isolate psychoactive cannabinoid effects from placebo.
• Depression scores improved, but researchers noted this may reflect overall symptom reduction rather than direct antidepressant action.

The study didn't track adverse events or cannabis-drug interactions, a gap that limits its clinical applicability. Radiation oncologists have flagged potential interactions between THC and certain chemotherapy agents, though no such effects were reported in this cohort.

For full background on this research area, see the CannIntel topic hub on cannabis cancer treatment.

Implications for Oncology Practice and State Programs

The findings add to a growing body of real-world evidence supporting cannabis as a palliative tool in cancer care. Clinical adoption remains uneven across state medical programs. Only 38 states include cancer as a qualifying condition for medical cannabis. Physician participation rates vary widely.

Kentucky, where the study was conducted, launched its medical cannabis program in January 2025 under HB 136. Cancer is a qualifying condition, but the state's limited dispensary rollout has constrained patient access. This University of Kentucky study may accelerate physician buy-in as the program matures.

Nationally, oncologists have been slower to recommend cannabis than physicians treating chronic pain or epilepsy, citing the lack of FDA-approved cannabis medicines beyond Epidiolex and Marinol. The 80% efficacy rate documented here is higher than many synthetic cannabinoid trials. Whole-plant formulations may offer advantages in symptom control.

Watch for whether the National Cancer Institute or ASCO issue updated guidance on cannabis in supportive oncology care. Current NCI guidance acknowledges cannabis use but stops short of clinical recommendations, a stance that may shift as state-level observational data accumulates.